反応式
[OH-:1].[K+].Cl.[NH2:4]O.[CH2:6]([N:13]([S:20]([N:23]1[CH2:28][CH2:27][N:26]([C:29]2[CH:34]=[CH:33][C:32]([Cl:35])=[CH:31][CH:30]=2)[CH2:25][CH2:24]1)(=[O:22])=[O:21])[C@H:14]([CH3:19])[C:15](OC)=[O:16])[C:7]1[CH:12]=[CH:11][CH:10]=[CH:9][CH:8]=1.ClC1C=CC(OC2CCNCC2)=NC=1.ClC1C=CC(N2CCNCC2)=CC=1.Cl>CO.C(Cl)Cl>[OH:1][NH:4][C:15](=[O:16])[C@H:14]([N:13]([CH2:6][C:7]1[CH:8]=[CH:9][CH:10]=[CH:11][CH:12]=1)[S:20]([N:23]1[CH2:24][CH2:25][N:26]([C:29]2[CH:34]=[CH:33][C:32]([Cl:35])=[CH:31][CH:30]=2)[CH2:27][CH2:28]1)(=[O:22])=[O:21])[CH3:19]参加物
反応物 6
生成物 1
試薬・触媒・溶媒 2
実験手順
A solution of potassium hydroxide (1.6 g, 29.2 mmol) in methanol (9.8 ml) was added to a solution of hydroxylamine hydrochloride (1.02 g, 14.6 mmol) in methanol (9.8 ml) at 0° C. After 5 min., a solution of methyl 2-(R)-{benzyl-[4-(4-chlorophenyl)piperazine-1-sulfonyl]amino}-propionate (1.101 g, 2.44 mmol) in methanol (9.8 ml), [prepared as described in Example 2, Step, 2, but replacing D-valinesulfamoyl chloride methyl ester and 4-(5-chloropyridin-2-yloxy)piperidine with D-alaninesulfamoyl chloride methyl ester and 4-(4-chlorophenyl)-piperazine respectively, followed by benzylation as described in Example 4] was added and the reaction temperature was allowed to rise to RT. After 5 h, the reaction mixture was diluted with methylene chloride (147 ml) and neutralized with 10% aqueous HCl. The solvent was removed in vacuo and the residue was dissolved in methanol. The insoluble salts were filtered off and N-hydroxy-2-(R)-{benzyl-[4-(4-chlorophenyl)piperazine-1-sulfonyl]amino}-propionamide was isolated using reverse phase preparative HPLC (20-70% acetonitrile/0.1% aqueous trifluoroacetic acid) as a crystalline solid (23%).
後処理
- additionwas added
- customto rise to RT
- waitAfter 5 h
- customThe solvent was removed in vacuo
- dissolutionthe residue was dissolved in methanol
- filtrationThe insoluble salts were filtered off
出典と根拠
- ORDレコード
- ord-7b8d7f084bcb40ac880db4910054a7e0
- 出典データセット
- uspto-grants-2002_04
- 特許番号
- US06376506B1
関連ノート
読み込み中…